This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Please Contact Us with any questions or comments.
Dr. Jeremy Paul Cetnar is a medical oncologist at the Knight Cancer Institute, OHSU Health, and the OHSU School of Medicine in Portland, Oregon. As part of the lung cancer team, he meets with other oncologists, surgeons, radiation oncologists, and other healthcare professionals three times a month to discuss each patient’s case and provide them with the best care possible.
Dr. Cetnar’s care of lung cancer patients begins with advanced testing and molecular analysis to pinpoint patients’ lung cancer type, then create a treatment plan that may include a combination of radiation therapy, chemotherapy, immunotherapy, or surgery. Dr. Cetnar also treats patients with malignant pleural mesothelioma and has participated in professional panels discussing the most innovative options for this rare and challenging disease.
Education and Career
Dr. Cetnar earned his medical degree at Loyola University Chicago Stretch School of Medicine, then completed his internship and residency in Internal Medicine at Oregon Health and Science University. He completed a fellowship in Hematology and Medical Oncology at the University of Pennsylvania Health System and then completed the rigorous Penn Master of Science in Health Policy Research at the University of Pennsylvania School of Medicine.
In addition to his role on the lung cancer team, Dr. Cetnar is an associate professor at the OHSU School of Medicine and a member of the Knight Cancer Translational Oncology Program. He is also the program leader of the OHSU Hematology and Medical Oncology Fellowship Program and a member of the American Society of Clinical Oncology.
Dr. Cetnar is actively involved in research through the Knight Cancer Institute and the Knight Cancer Translational Oncology Program. His most recent research includes:
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC, Journal of Thoracic Oncology 2021. Fiona BlackhallKevin JaoLaurent GreillierByoung Chul ChoKonstantin PenkovNoemi ReguartMargarita MajemKristiaan NackaertsKonstantinos SyrigosKarin HansenWolfgang SchuetteJeremy CetnarFederico CappuzzoIsamu OkamotoMustafa ErmanSeppo W. LangerTerufumi KatoHarry GroenZhaowen SunYan LuoPoonam TanwaniLaura CaffreyPhilip KomarnitskyNiels Reinmuth
Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors, Scientific Reports Dec 2021. Matthew S. DietzThomas L. SuttonBrett S. WalkerCharles E. GastLuai ZarourSidharth K. SenguptaJohn R. SwainJennifer EngMichael ParappillyKristen LimbachAriana SattlerErik BurlingameYuki ChinAustin GowerJose L.Montoya MiraAjay SapreYu Jui ChiuDaniel R. ClayburghSu Ellen J. PommierJeremy P. CetnarJared M. FischerJerry J. JaboinRodney F. PommierBrett C. SheppardV. Liana TsikitisAlison H. SkaletSkye C. MayoCharles D. LopezJoe W. GrayGordon B. MillsZahi MitriYoung Hwan ChangKoei ChinMelissa H. Wong
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer, Cancer Oct 15, 2020. Tian ZhangMichael R. HarrisonPeter H. O’DonnellAjjai S. AlvaNoah M. HahnLeonard J. ApplemanJeremy CetnarJohn M. BurkeMark T. FlemingMatthew I. MilowskyAmir MortazaviNeal ShoreGuru P. SonpavdeEmmett V. SchmidtBojena BitmanVeerendra MunugalavadlaRaquel IzumiPriti PatelJanet StaatsCliburn ChanKent J. WeinholdDaniel J. George
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer, Lung Cancer Jan 2020. David E. Gerber. Ross CamidgeDaniel MorgenszternJeremey CetnarRonan J. KellySuresh S. RamalingamDavid R. SpigelWoondong JeongPier P. ScaglioniSong ZhangMarilyn LiDavid T. WeaverLouis VaikusMitchell KeeganJoanna C. HorobinTimothy F. Burns
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance, Proceedings of the National Academy of Sciences of the United States of America Jun 2, 2020. Joshi J. AlumkalDuanchen SunEric LuTomasz M. BeerGeorge V. ThomasEmile LatourRahul AggarwalJeremy CetnarCharles J. RyanShaadi TabatabaeiShawna BaileyClaire B. TurinaDavid A. QuigleyXiangnan GuanAdam FoyeJack F. YoungrenJoshua UrrutiaJiaoti HuangiAlana S. WeinsteinVerena FriedlMatthew RettigRobert E. ReiterDaniel E. SprattMartin GleavChristopher P. EvansJoshua M. StuartYiyi ChenFelix Y. FengEric J. SmallOwen N. WitteZheng XiaGet Your FREE Mesothelioma Packet
Written by Terri Oppenheimer
Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.